TAE Life Sciences
Foothill Ranch
About TAE Life Sciences
TAE Life Sciences is developing a novel biological-targeting radiation therapy based on Boron Neutron Capture Therapy (BNCT) to improve the lives of patients with rapidly spreading, invasive and recurrent cancers that do not respond to other cancer therapies. TLS is the only company with a comprehensive target drug and neutron technology product portfolio to enable next-generation combination cancer therapy as a first-line treatment for patients globally.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $70.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Jun 2020)
- Website: taelifesciences.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Hospital, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/tae-life-sciences-124744 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.